Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data

Cancer Research and Treatment : Official Journal of Korean Cancer Association
Do Young KimSeung Kew Yoon

Abstract

The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study). Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of paper or electronic version were used to record safety and efficacy data from all patients. More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child-Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median overall survival (OS) and time to progression (TTP) were 8.5 months and 2.5 months. In Child-Pugh A patients, the median OS and TTP were 10.2 months and 2.5 months. The most frequent treatment-emergent drug-related adverse event was hand-foot skin reaction (31.7%), followed by diarrhea (18.0%). The incidence of treatme...Continue Reading

References

Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Mar 5, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN American Association for the Study of Liver Diseases
Jul 16, 2011·Journal of Hepatology·Valentina SantiFranco Trevisani
Mar 20, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver, UNKNOWN European Organisation For Research And Treatment Of Cancer
Feb 14, 2013·The Journal of Contemporary Dental Practice·S Jayaprada ReddyG Vikram Reddy
Jun 1, 2012·Liver Cancer·Do Young Kim, Kwang-Hyub Han
Feb 15, 2015·Critical Reviews in Oncology/hematology·Kuo-Shyang JengChi-Juei Jeng

❮ Previous
Next ❯

Citations

Nov 21, 2017·Clinical and Molecular Hepatology·Imane El Dika, Ghassan K Abou-Alfa
Mar 17, 2017·Targeted Oncology·Gillian M Keating
Dec 24, 2018·Expert Review of Anticancer Therapy·Bernard EscudierMasatoshi Kudo
Nov 11, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Pil Soo SungSi Hyun Bae

❮ Previous
Next ❯

Software Mentioned

GIDEON

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.